Last updated on March 2019

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer


Brief description of study

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.

Clinical Study Identifier: NCT02779751

Find a site near you

Start Over

Highlands Oncology Group

Fayetteville, AR United States
  Connect »

Univ of California San Francisco

San Francisco, CA United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Gustave Roussy

Villejuif Cedex, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.